Source: Proteomics International Laboratories
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Proteomics International (PIQ) is preparing to present its latest results from the company’s novel blood test for oesophageal adenocarcinoma
  • The company will showcase results from its PromarkerEso blood test at the 19th ISDE World Congress for Esophageal Diseases in Toronto, Canada
  • Oesophageal adenocarcinoma is a lethal disease, with a mere five-year survival rate of just 20 per cent
  • Shares last traded at 90 cents

Proteomics International (PIQ) has made significant progress in the fight against oesophageal cancer as it prepares to present at the 19th ISDE World Congress for Esophageal Diseases in Toronto, Canada.

The company will showcase findings from its novel blood test, PromarkerEso, designed to detect this deadly cancer.

Oesophageal adenocarcinoma is a lethal disease, with a mere five-year survival rate of just 20 per cent. It often originates from chronic acid reflux, underscoring the critical importance of early detection.

Current screening methods involve costly specialist endoscopy procedures, which can amount to US$2750 per patient in the United States.

The test offers new hope for early and accurate detection of oesophageal adenocarcinoma, the most common form of oesophageal cancer.

“We’ve refined our diagnostic models to correctly identify 89 per cent of patients with oesophageal adenocarcinoma and 92 per cent of patients without the disease,” PIQ Managing Director Dr Richard Lipscombe said.

“This means we could have a simple blood test to determine who would benefit from an endoscopy.”

PromarkerEso utilises protein biomarkers in the blood to diagnose both oesophageal adenocarcinoma and its precursor condition, Barrett’s oesophagus.

Approximately 10-15 per cent of patients with chronic acid reflux develop Barrett’s oesophagus, significantly increasing their risk of oesophageal cancer.

The potential impact of this test is profound, not only in saving lives but also in reducing healthcare costs.

Proteomics International is currently working on streamlining the biomarker measurements for clinical use in the United States.

PIQ is also collaborating with key opinion leaders (KOLs) to facilitate the early adoption of PromarkerEso.

Proteomics International shares last traded at 90 cents.

PIQ by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Consumer Discretionary rises ahead of interest rates decision | June 14, 2024

The ASX200 is down a third of a per cent to close the week. All sectors…
The Market Online Video

ASX Market Update: ASX slips 0.3%, Discretionary is the only sector to rise | 14 June, 2024

The ASX200 is trading down around 0.3%. The discretionary sector has made gains of 0.3%, all…

Week 24 Wrap: US contagion sentiment not so contagious; iron ore remains pressured

It was, overall, a lacklustre week for the ASX. We only saw one green day on…
The Market Online Video

Geology is King: Sun Silver says Maverick Springs will outshine high-grade Australian mines

Sun Silver Ltd (ASX:SS1) is seeking gold, silver and pathfinder elements at their Maverick Springs project…